Log in  First Connection?

Blood CancerArchives

Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia
Blood Cancer
 4 min.

 Published on 22/04/2025 |  Original article (Full-text)  | Xavier Thomas   et al. | Oncology and Therapy 2025; aop: 10.1007/s40487-025-00339-1

T cell lineage acute lymphoblastic leukemia (ALL) is characterized by immunophenotypic and molecular high diversity. T-ALL represents 15% of pediatric and 25% of adult newly diagnosed ALL cases [1]. In frontline therapy, all patients with T-ALL are treated with similar multiagent chemotherapy regimens...

Analysis of hemolysis-associated acute myeloid leukemia genes obtained using weighted gene co-expression network analysis and a Mendelian randomization study
Blood Cancer
 4 min.

 Published on 15/04/2025 |  Original article (Full-text)  | Zhang Rui et al. | Blood research 2025; 60(1): 24

Acute myeloid leukemia (AML) is preceded by malignant clonal expansion of progenitor cells with impaired differentiation and is associated with the highest proportion of deaths among all types of leukemia [1, 2, 3–4]. In the United States, in 2024, there were 20,800 new cases of AML, accounting...

Response to daratumumab-retreatment in patients with multiple myeloma
Blood Cancer
 4 min.

 Published on 08/04/2025 |  Original article (Full-text)  | Souren Laura et al. | Annals of Hematology 2025; 104(2): 1059-67

Multiple myeloma (MM) is a malignant hematologic neoplasia characterized by bone marrow infiltration of monoclonal plasma cells. The secreted functionless monoclonal immunoglobulins or light chains can be detected as the M-protein and clonally increased light chains in serum and/or urine [1, 2]. MM remains...

Daratumumab/Bortezomib/Thalidomide/Dexamethasone in Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Blood Cancer
 1 min.

 Published on 01/04/2025 |  Original article (Full-text)  | Corre, Jill et al. | Blood 2025; AOP:10.1182/blood.2024027620

Previous results from CASSIOPEIA (NCT02541383) demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance versus observation...

Proceedings of the 4th European Congress controversies in Leukemias, held in Brussels, Belgium, 20-21 November, 2023.
Blood Cancer
 1 min.

 Published on 24/09/2024 |  Synthesis  | The ContentGeneMD editorial committee

AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...